Evidence map›Paper›PMID 38454800›Full record

ArticleJournal of cellular and molecular medicine2024

SGLT2i improves kidney senescence by down-regulating the expression of LTBP2 in SAMP8 mice.

Lu Zeng, Jie Li, Fanfan Gao, Yangyang Song, Limin Wei, Ning Qu, Shengnan Chen, Xue Zhao, Zitong Lei, Wenya Cao and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. The Effects of SNPs in theVeterinary medicine international · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Lu ZengDepartment of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China.ORCID 0000-0002-4131-0748
Jie LiDepartment of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China.
Fanfan GaoDepartment of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China.
Yangyang SongDepartment of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China.
Limin WeiDepartment of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China.
Ning QuDepartment of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China.
Shengnan ChenDepartment of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China.
Xue ZhaoDepartment of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China.
Zitong LeiDepartment of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China.
Wenya CaoDepartment of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China.
Lei ChenDepartment of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China.
Hongli JiangDepartment of Critical Care Nephrology and Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shannxi, China.
First Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

National Natural Science Foundation of China 81870507
6 · The paper itself

Abstract

Senescent kidney can lead to the maladaptive repairment and predispose age-related kidney diseases. Here, we explore the renal anti-senescence effect of a known kind of drug, sodium-dependent glucose transporters 2 inhibitor (SGLT2i). After 4 months intragastrically administration with dapagliflozin on senescence-accelerated mouse prone 8 (SAMP8) strain mice, the physiologically effects (lowering urine protein, enhancing glomerular blood perfusion, inhibiting expression of senescence-related biomarkers) and structural changes (improving kidney atrophy, alleviating fibrosis, decreasing glomerular mesangial proliferation) indicate the potential value of delaying kidney senescence of SGLT2i. Senescent human proximal tubular epithelial (HK-2) cells induced by H

Indexed as

Kidney DiseasesSodium-Glucose Transporter 2 InhibitorsAnimalsBenzhydryl CompoundsGlucosidesHumansKidneyLatent TGF-beta Binding ProteinsMiceBenzhydryl CompoundsdapagliflozinGlucosidesLatent TGF-beta Binding ProteinsLTBP2 protein, humanSodium-Glucose Transporter 2 InhibitorsdapagliflozinkidneyLTBP2SAMP8senescenceSGLT2i

Identifiers

PMID38454800
PMCPMC10921069
OpenAlexW4392590944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.